Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

818.93 -10.81 (-1.30%)
Official Closing Price Updated: 7:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Biden Administration Unveils Plan To Provide Generic Drugs for $2 to Medicare Recipients
The Biden administration's proposed Medicare $2 Drug List Model aims to provide low-cost generic drugs for seniors and people with disabilities, with copayments capped at $2 per month for essential... 
Via Benzinga
CVS, UnitedHealth Request FTC Chair Recusal Amid Ongoing Pharmacy Benefit Managers Lawsuit
The FTC has filed a formal complaint accusing CVS, Cigna, and UnitedHealth of engaging in anti-competitive practices that inflate insulin prices. The complaint claims the PBMs' focus on rebates raises... 
Via Benzinga
What's Going With WeightWatchers Stock On Wednesday?
WeightWatchers stock rises after the company announces compounded semaglutide offerings, addressing GLP-1 shortages while grappling with insurance denials and FDA criticism over drug access. 
Via Benzinga
Exposures Product Safety
Don’t Sleep on Skye Bioscience—This Weight Loss Drug Could Soar
Skye Bioscience has incredible potential upside, according to Wall Street analysts. It is striving to make a new weight loss drug, that could work with GLP-1s. 
Via MarketBeat
(LLY) - Analyzing Eli Lilly's Short Interest
Via Benzinga
Evaluating Eli Lilly Against Peers In Pharmaceuticals Industry
Via Benzinga
Cracking The Code: Understanding Analyst Reviews For Eli Lilly
Via Benzinga
Why Eli Lilly Was Such a Healthy Stock Today
The pharmaceutical giant's weight loss medication Zepbound was in the spotlight again Tuesday. 
Via The Motley Fool
FDA Sparks Controversy With Sudden Removal Of Eli Lilly's Weight Loss Drug From Shortage List
FDA faces legal action after removing Tirzepatide from the shortage list without following required procedures, sparking concerns over patient access to the compounded diabetes and obesity treatment. 
Via Benzinga
Exposures Product Safety
Hims & Hers Stock Joins S&P 600: Is More Upside on the Horizon?
There is now a new reason to look into Hims & Hers stock for additional upside, including the new addition to the S&P 600 index alongside double-digit growth. 
Via MarketBeat
Topics Stocks
Exposures US Equities
With Its GLP-1 Drugs No Longer in a Shortage, Is Now the Time to Buy Eli Lilly Stock?
Growth for its GLP-1 weight loss drugs continues to be robust. 
Via The Motley Fool
UNH: A Solid Healthcare Play In A Rotational Market
The blistering hot theme in markets right now is obviously the China trade, and this means investor capital is being allocated towards the Hang Seng, China ADRs, and for institutions that have access,... 
Via Talk Markets
Billion-Dollar News for Eli Lilly Stock Investors
Eli Lilly shares have soared thanks to excitement about the company's position in the weight loss drug market. 
Via The Motley Fool
Biotech Stocks Poised For Another Big Move In Q4
The healthcare sector can be a safe haven if volatility increases. 
Via Talk Markets
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Regeneron Chief Flags Health Risks with Popular Weight-Loss Medications Like Ozempic, Says Company Targets Muscle Preservation For Its Obesity Drugs
Regeneron's CSO George Yancopoulos warns that GLP-1 weight-loss drugs like Ozempic may lead to rapid muscle loss, increasing health risks. Regeneron is investigating therapies to offset these effects... 
Via Benzinga
2 Next-Gen Weight Loss Stocks That Are Worth Buying Right Now
One of these businesses is a risky play, but the other is very likely to succeed. 
Via The Motley Fool
Economist Justin Wolfers Points To Obesity Rate Decline As Ozempic And Wegovy Spur Historic Shift In Fight Against Obesity — Has US Reached A Turning Point?
Renowned economist Justin Wolfers highlighted this significant shift on social media platform X, stating, "From the Department of Things Really Are Getting Better: The U.S. obesity rate may have... 
Via Benzinga
Want $1 Million in Retirement? 3 Stocks to Buy Now and Hold for Decades
Investors can find market-trouncing blue chip stocks in the healthcare industry. 
Via The Motley Fool
Hims & Hers Health Asserts Demand For Its Compounded Weight Loss Offering To Continue Despite Resolved Supply Shortages
The FDA has resolved Eli Lilly's tirzepatide shortage, but localized supply issues persist. Meanwhile, Hims & Hers Health's Q3 2024 revenue is expected to exceed projections as concerns rise over... 
Via Benzinga
Exposures Product Safety
England's NHS Proposes Phased Rollout of Eli Lilly's Mounjaro, Considers Digital Services to Boost Access
NHS England plans a phased rollout of tirzepatide to treat severe obesity, with early trials showing significant weight loss. Digital clinics and multidisciplinary teams will deliver the drug to... 
Via Benzinga
As Weight-Loss Drugs Battle, Upstart Viking Therapeutics Threatens Eli Lilly, Novo Nordisk, Pfizer
Viking Therapeutics is an upstart in the weight-loss drugs space. But it's catching attention. 
Via Investor's Business Daily
Massive News for Hims & Hers Stock: The Truth About Today's Move
Hims & Hers may not be hurt by GLP-1 news the way investors think. 
Via The Motley Fool
Texas Attorney General Sues Insulin Manufacturers and Pharmacy Benefit Managers Over Price-Fixing Conspiracy That Increased Prices by 1,000%
Texas Attorney General Ken Paxton sues major insulin manufacturers and PBMs, accusing them of conspiring to inflate insulin prices by as much as 1,000%, violating Texas law and harming diabetes... 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Popular Weight Loss Drugs Like Ozempic Show Gap Between Clinical Trial Promises And Real-World Use, Study Reveals
Real-world studies on GLP-1s like Ozempic show lower weight loss than clinical trials, with high discontinuation rates due to adverse effects, costs, and unmet expectations, raising concerns about... 
Via Benzinga
Hims & Hers Health Stock Is Tumbling Thursday: Here's Why
Hims & Hers Health Inc (NYSE:HIMS) shares are trading lower Thursday after the U.S. Food and Drug Administration removed Eli Lilly And Co's (NYSE:LLY) weight-loss and diabetes drugs from its shortage... 
Via Benzinga
This IPO Biotech Stock Could Be the Next Eli Lilly
BioAge has its eyes on a handful of truly gargantuan markets. 
Via The Motley Fool
Topics Initial Public Offering
Exposures Securities Market
Eli Lilly Leads S&P Health Care Stocks With 1,241% Gain. But The Others Aren't Slackers.
Eli Lilly has gained markedly over the past decade. But it's not the only S&P 500 health care stock to notch a bullish gain. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Tandem Diabetes Insulin Pump Demand to Surge Despite Popular Demand Of Weight Loss Drugs, Bullish Analyst Says
RBC Capital Markets initiates coverage on Tandem Diabetes Care (TNDM) with an Outperform rating and $65 price target, citing growth opportunities in the U.S. Type 1 and Type 2 diabetes markets, product... 
Via Benzinga
Eli Lilly Commits $4.5B To New Facility, Banking On Mounjaro, Zepbound's Weight Loss Success Despite Short-Term Stock Challenges
Eli Lilly (NYSE:LLY) investing $4.5B to create Lilly Med Foundry, with goal of faster drug pipeline and scaling molecules to medicines. Stock outlook mixed. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.